Mardelle U, Bretaud N, Daher C, Feuillet V
Front Immunol. 2024; 15:1335387.
PMID: 38433844
PMC: 10905387.
DOI: 10.3389/fimmu.2024.1335387.
Covenas R, Rodriguez F, Robinson P, Munoz M
Int J Mol Sci. 2023; 24(21).
PMID: 37958914
PMC: 10650658.
DOI: 10.3390/ijms242115936.
Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M
Curr Med Chem. 2023; 31(39):6487-6509.
PMID: 37861026
DOI: 10.2174/0109298673261625230924114406.
Isorna I, Gonzalez-Moles M, Munoz M, Esteban F
J Clin Med. 2023; 12(19).
PMID: 37835053
PMC: 10573850.
DOI: 10.3390/jcm12196409.
Cao X, Yang Y, Zhou W, Wang Y, Wang X, Ge X
BMC Cancer. 2023; 23(1):471.
PMID: 37221457
PMC: 10204192.
DOI: 10.1186/s12885-023-10954-8.
ADRB2 Regulates the Proliferation and Metastasis of Gastrointestinal Stromal Tumor Cells by Enhancing the ETV1-c-KIT Signaling.
Chen S, Wu F, Zhang J, Zhu J, Zhou X, Zhi X
J Oncol. 2023; 2023:6413796.
PMID: 36778918
PMC: 9918370.
DOI: 10.1155/2023/6413796.
Neural regulations of the tumor microenvironment.
Restaino A, Vermeer P
FASEB Bioadv. 2022; 4(1):29-42.
PMID: 35024571
PMC: 8728107.
DOI: 10.1096/fba.2021-00066.
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis.
Rodriguez E, Pei G, Kim S, German A, Robinson P
Cancers (Basel). 2021; 13(15).
PMID: 34359773
PMC: 8345440.
DOI: 10.3390/cancers13153871.
Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
Recio R, Lerena P, Pozo E, Calderon-Montano J, Burgos-Moron E, Lopez-Lazaro M
J Med Chem. 2021; 64(14):10350-10370.
PMID: 34236855
PMC: 8529873.
DOI: 10.1021/acs.jmedchem.1c00793.
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?.
Munoz M, Covenas R
Cancers (Basel). 2020; 12(9).
PMID: 32962202
PMC: 7564414.
DOI: 10.3390/cancers12092682.
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Munoz M, Covenas R
J Clin Med. 2020; 9(6).
PMID: 32492831
PMC: 7355887.
DOI: 10.3390/jcm9061659.
The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.
Isorna I, Esteban F, Solanellas J, Covenas R, Munoz M
Eur J Histochem. 2020; 64(2).
PMID: 32363847
PMC: 7196935.
DOI: 10.4081/ejh.2020.3117.
Dangerous Liaison: Helicobacter pylori, Ganglionitis, and Myenteric Gastric Neurons: A Histopathological Study.
Sticlaru L, Staniceanu F, Cioplea M, Nichita L, Bastian A, Micu G
Anal Cell Pathol (Amst). 2020; 2019:3085181.
PMID: 32082967
PMC: 7012220.
DOI: 10.1155/2019/3085181.
Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2.
Zhang X, Zhang Y, He Z, Yin K, Li B, Zhang L
Cell Death Dis. 2019; 10(11):788.
PMID: 31624248
PMC: 6797812.
DOI: 10.1038/s41419-019-2030-2.
Correlation of Clinicopathological Characteristics of Breast Carcinoma and Depression.
Ilic M, Mitrovic S, Vuletic M, Radivojcevic U, Janjic V, Stankovic V
Healthcare (Basel). 2019; 7(3).
PMID: 31547382
PMC: 6787716.
DOI: 10.3390/healthcare7030107.
miR-206 Promotes Cancer Progression by Targeting Full-Length Neurokinin-1 Receptor in Breast Cancer.
Zhou Y, Wang M, Tong Y, Liu X, Zhang L, Dong D
Technol Cancer Res Treat. 2019; 18:1533033819875168.
PMID: 31506061
PMC: 6740052.
DOI: 10.1177/1533033819875168.
The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.
Majkowska-Pilip A, Halik P, Gniazdowska E
Pharmaceutics. 2019; 11(9).
PMID: 31480582
PMC: 6781293.
DOI: 10.3390/pharmaceutics11090443.
Design, Synthesis, and Evaluation of a Neurokinin-1 Receptor-Targeted Near-IR Dye for Fluorescence-Guided Surgery of Neuroendocrine Cancers.
Kanduluru A, Srinivasarao M, Low P
Bioconjug Chem. 2016; 27(9):2157-65.
PMID: 27529726
PMC: 5343518.
DOI: 10.1021/acs.bioconjchem.6b00374.
Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Munoz M, Covenas R
Saudi J Gastroenterol. 2016; 22(4):260-8.
PMID: 27488320
PMC: 4991196.
DOI: 10.4103/1319-3767.187601.
High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis.
Chen X, Ru G, Ma Y, Xie J, Chen W, Wang H
Onco Targets Ther. 2016; 9:3595-602.
PMID: 27366097
PMC: 4913971.
DOI: 10.2147/OTT.S102356.